Stay up-to-date on the latest stock market upgrades and downgrades on Wall Street, including companies like Roku, Palo Alto ...

Alzheimer's wonder drugs aren't yet delivering on their promise. American researchers have come up with a brand new idea, a ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

There's no cure for this disease, but now there is some hope for people and their families who are battling the illness in ...

Long-term use of cardiovascular drugs may reduce dementia risk in older adults by up to 25%, while antiplatelet drugs could ...

Biogen Inc. (NASDAQ:BIIB) is a biotechnology company that makes and sells treatments for a variety of diseases such as ...

In March 2019, Biogen and partner pharma company Eisai announced they were ending trial that Geri was enrolled in. This was based on an interim analysis that led the company to scrap the drug, telling ...

I think I've just always liked science,” says Frank Longo, Professor of Neurology and Neurological Sciences and Professor, by ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 22% bullish and 66%, bearish. Out ...